Countaway J L, McQuilkin P, Gironès N, Davis R J
Program in Molecular Medicine, University of Massachusetts Medical School, Worcester 01655.
J Biol Chem. 1990 Feb 25;265(6):3407-16.
The major sites of serine and threonine phosphorylation of the human epidermal growth factor (EGF) receptor observed in intact cells are Thr654, Thr669, Ser1046, and Ser1047. Phosphorylation of the EGF receptor is increased at these sites in cells treated with platelet-derived growth factor or phorbol ester. This increase in EGF receptor phosphorylation is associated with an inhibition of the high affinity binding of EGF to cell surface receptors and an inhibition of the receptor tyrosine protein kinase activity. In order to test the hypothesis that the phosphorylation of the EGF receptor is mechanistically related to the modulation of EGF receptor function, we replaced the major sites of serine and threonine phosphorylation with alanine residues. EGF receptors containing single point mutations or multiple mutations were expressed in Chinese hamster ovary cells. Analysis of the regulation of the EGF receptor tyrosine protein kinase activity demonstrated that phorbol ester caused an inhibition of the tyrosine phosphorylation of wild-type receptors and receptors lacking Thr669, Ser1046, or Ser1047. In contrast, the inhibition of EGF receptor tyrosine phosphorylation caused by phorbol ester was not observed for any of the mutated EGF receptors that lacked Thr654. These data are consistent with the hypothesis that the phosphorylation of the EGF receptor at Thr654 is required for the inhibition of the receptor tyrosine protein kinase activity caused by phorbol ester. Investigation of the apparent affinity of the EGF receptor demonstrated that treatment with phorbol ester caused an inhibition of the high affinity binding of 125I-EGF to cells expressing wild-type EGF receptors and each of the mutated EGF receptors examined. We conclude that the regulation of the apparent affinity of the EGF receptor is independent of the major sites of serine and threonine phosphorylation of the EGF receptor.
在完整细胞中观察到的人表皮生长因子(EGF)受体丝氨酸和苏氨酸磷酸化的主要位点是苏氨酸654、苏氨酸669、丝氨酸1046和丝氨酸1047。在用血小板衍生生长因子或佛波酯处理的细胞中,这些位点的EGF受体磷酸化增加。EGF受体磷酸化的这种增加与EGF与细胞表面受体的高亲和力结合的抑制以及受体酪氨酸蛋白激酶活性的抑制相关。为了检验EGF受体磷酸化在机制上与EGF受体功能调节相关的假说,我们用丙氨酸残基取代了丝氨酸和苏氨酸磷酸化的主要位点。含有单点突变或多个突变的EGF受体在中国仓鼠卵巢细胞中表达。对EGF受体酪氨酸蛋白激酶活性调节的分析表明,佛波酯可抑制野生型受体以及缺乏苏氨酸669、丝氨酸1046或丝氨酸1047的受体的酪氨酸磷酸化。相反,对于任何缺乏苏氨酸654的突变EGF受体,均未观察到佛波酯引起的EGF受体酪氨酸磷酸化抑制。这些数据与以下假说一致:佛波酯引起的受体酪氨酸蛋白激酶活性抑制需要EGF受体在苏氨酸654处磷酸化。对EGF受体表观亲和力的研究表明,用佛波酯处理可抑制125I-EGF与表达野生型EGF受体以及所检测的每个突变EGF受体的细胞的高亲和力结合。我们得出结论,EGF受体表观亲和力的调节独立于EGF受体丝氨酸和苏氨酸磷酸化的主要位点。